
CAS 149690-05-1
:Sacubitril Sodium
Description:
Sacubitril sodium is a pharmaceutical compound primarily used in the treatment of heart failure. It functions as a neprilysin inhibitor, which enhances the levels of natriuretic peptides, leading to vasodilation and diuresis. This mechanism helps to reduce the strain on the heart and improve overall cardiac function. Sacubitril sodium is typically administered in combination with valsartan, an angiotensin receptor blocker, to provide a synergistic effect in managing heart failure. The compound is characterized by its sodium salt form, which enhances its solubility and bioavailability. In terms of physical properties, sacubitril sodium is a white to off-white powder, and it is soluble in water. Its pharmacokinetics involve rapid absorption and metabolism, with a half-life that supports once or twice daily dosing. As with any medication, potential side effects may include hypotension, hyperkalemia, and renal impairment, necessitating careful monitoring during treatment. Overall, sacubitril sodium represents a significant advancement in heart failure management, improving patient outcomes through its unique mechanism of action.
- Sacubitril Sodium Salt
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
Sacubitril sodium
CAS:<p>Sacubitril sodium (AHU-377) is potent NEP inhibitor with an IC50=5 nM for the treatment of heart failure or in combination with antihypertensive agents.</p>Formula:C24H28NNaO5Purity:99.97%Color and Shape:SolidMolecular weight:433.47Sacubitril Sodium Salt
CAS:Formula:C24H28NO5·NaColor and Shape:White To Off-WhiteMolecular weight:433.473Sacubitril sodium
CAS:<p>Inhibitor of metalloendopeptidase neprilysin</p>Formula:C24H28NNaO5Purity:Min. 95%Color and Shape:PowderMolecular weight:433.47 g/molSacubitril-13C4 Sodium
CAS:Controlled Product<p>Applications Sacubitril-13C4 Sodium is a derivative Isotope labelled Sacubitril (S080895), which is an antihypertensive drug used in combination with Valsartan (V095750). The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure.<br>References McMurray, J., et al.: N. Eng. J. Med., 371 (2014);<br></p>Formula:C4C20H28NNaO5Color and Shape:NeatMolecular weight:437.443






